Compounded Rx Isn't Grey Market, But Most Of The Internet Thinks It Is

the conversation that keeps going wrong

If you've tried to talk to a primary care doctor about peptide therapy, compounded HRT, methylene blue, or anything else outside the FDA-approved-drug-and-brand-name-pharma category, you've probably had some version of this conversation:

You bring up the medication. The doctor gets a slightly skeptical look. They say something like, that's not FDA-approved, or that's the unregulated space, or I'm not really comfortable with that. The implication (sometimes explicit, often not) is that what you're asking about is in the same category as research-chemical websites and shady supplement stores.

That conversation reflects a real misunderstanding about how the US pharmaceutical regulatory system actually works. There's a meaningful difference between three categories that get conflated as one. The distinction is worth knowing, both for your own decision-making and for being able to push back productively when a clinician collapses them.

the three categories that get confused

Category 1: FDA-approved drugs. Manufactured by pharmaceutical companies at scale, evaluated through the New Drug Application (NDA) process, indication-specific, manufactured under strict quality controls. Examples: Wegovy, Vyleesi, Eliquis, basically anything with a brand name and TV commercials. These have FDA approval for specific indications. The regulatory system around them is robust and well-known.

Category 2: Compounded medications. Made by compounding pharmacies, facilities licensed and regulated under specific federal and state frameworks. The two main types: 503A compounding pharmacies (traditional, prescription-specific compounding, regulated primarily by state boards of pharmacy with FDA oversight) and 503B outsourcing facilities (larger-scale, FDA-registered, manufacturing-style compounding under FDA's Drug Quality and Security Act). Both are part of the legitimate prescription drug supply chain. Both have real regulatory oversight. Examples: most prescription-grade testosterone preparations, most bioidentical HRT, peptides like Sermorelin and PT-141, custom-dosed thyroid medication, custom-flavored pediatric formulations.^[1]

Category 3: Research chemicals / gray market. Substances sold by companies that explicitly market them as not for human use, typically via websites that disclaim any medical application. Examples: most of what you see if you Google peptide names, companies selling vials of BPC-157, TB-500, etc. with disclaimers. These aren't regulated as drugs because they're not legally drugs; they're chemicals sold for research purposes. The supply chain has no quality control, no purity guarantees, and no provider relationship.

The failure mode in primary care conversations is collapsing categories 2 and 3 into a single not-FDA-approved bucket. This isn't accurate, and the consequences are real.

what compounding pharmacies actually do

Compounding pharmacies have existed in the US for over a century. They predate the modern pharmaceutical industry. The original role (and a substantial role today) is creating customized medication for specific patient needs that mass-manufactured drugs don't address.

Custom dosing. A patient needs 12.5mg of a medication that only comes in 25mg tablets. Standard splitting is unreliable. A compounding pharmacy makes 12.5mg tablets.

Allergen-free formulations. A patient has a documented allergy to a dye, preservative, or filler in the commercial version of a medication. The compounding pharmacy makes the same active ingredient without the problematic excipient.

Alternative delivery forms. A patient can't swallow capsules but the medication only comes as a capsule. The compounding pharmacy makes a liquid or suspension version. Or makes a topical cream version of an oral medication where that delivery makes clinical sense.

Discontinued medications. A drug is no longer commercially manufactured, but specific patients still need it. The compounding pharmacy continues to make it for those patients.

Combination preparations. A patient needs two medications combined into a single preparation for compliance or specific clinical reasons. The compounding pharmacy makes the combination.

Medications not commercially available. Some active pharmaceutical ingredients are legitimately useful but don't have a commercial product because the market is too small for pharma manufacturer interest, or the indication is too specific, or the medication is off-patent and not commercially produced anymore. Compounded versions fill these gaps.

In all of these cases, the compounding pharmacy operates under regulations that include facility licensing, pharmacy practice standards, quality testing requirements (potency, sterility for injectable products, stability), recordkeeping requirements, and the prescription requirement that every compounded medication be made for a specific patient on a specific prescription from a specific licensed prescriber.

This is regulated medicine. It's not the same regulatory pathway as FDA-approved drugs, and the trial requirements are different. But it's not unregulated, and it's not gray-market.

the 503a vs 503b distinction

Two specific compounding categories are worth understanding because they often come up in the peptide and HRT conversation.

503A pharmacies. Traditional patient-specific compounding. These pharmacies make medications for specific prescriptions, in response to specific patient needs identified by specific prescribers. They're regulated primarily by state boards of pharmacy, with FDA oversight on specific categories of risk (sterility, controlled substances, certain restricted ingredients). Most of what people think of as the local compounding pharmacy is 503A.

503B outsourcing facilities. A newer category created by the Drug Quality and Security Act of 2013, in response to the New England Compounding Center tragedy. These are larger-scale compounders that operate more like manufacturers, registered directly with FDA, subject to GMP (Good Manufacturing Practice) standards similar to pharmaceutical manufacturers, and able to compound in batches without prescription-specific authorization. Many peptide telehealth platforms work with 503B facilities for the compounded peptides they distribute: Sermorelin, PT-141, NAD+, etc.

Both categories are legitimate. The 503B facilities are subject to more rigorous quality controls (FDA inspections, GMP standards, batch testing) but operate at larger scale. The 503A pharmacies are subject to less rigorous controls but have closer prescriber relationships and serve genuinely customized prescriptions.

Most legitimate peptide telehealth platforms (including Pepvio) work primarily with 503B facilities for the compounded medications they dispense. The compounded medications are made under FDA-registered manufacturing standards, with batch quality testing, in facilities regulated for this purpose. This is the operating reality of the compounded medication category, not the gray-market caricature.

why the conflation happens

If compounded medication is a legitimate regulatory category, why does the primary care conversation so often collapse it with gray-market research chemicals? A few real reasons.

Most primary care doctors don't have practical experience with compounding. Their pharmaceutical training and ongoing CME is dominated by FDA-approved commercial drugs. Compounded medications aren't taught in the same depth, and the practical familiarity isn't there. I don't know what's in that is a reasonable position for a clinician who didn't train on it.

Compounding has had legitimate quality scandals. The 2012 New England Compounding Center fungal meningitis outbreak killed 64 people and was a genuine compounding-pharmacy failure. The regulatory response (the 2013 DQSA, the creation of the 503B category) addressed the structural issues, but the reputational damage was real. Compounding has had problems is true; therefore all compounding is unregulated is a leap.

The peptide-specific gray market is large. The research-chemical world for peptides has become huge over the past decade. Bodybuilders ordering BPC-157 from internet vendors with disclaimers, biohackers self-administering compounds from unknown sources: this is real, it's not legitimate, and it's adjacent enough to the legitimate compounded peptide space that the categories get conflated. A clinician who has heard about someone's homebrew peptide regimen may legitimately conflate that with a prescription compounded peptide protocol because the active ingredient looks similar.

Marketing has confused things. Some compounding pharmacy advertising overpromises, frames things in ways that look like FDA-approved-drug marketing, or implies regulatory equivalences that aren't accurate. This makes it reasonable for skeptical clinicians to lump all of it together.

The boundary genuinely is fuzzy in some cases. When the same active ingredient (e.g., GLP-1s during the shortage period) is available both as an FDA-approved drug and as a compounded medication, the regulatory difference is real but the chemistry isn't, and that's hard to explain to a patient who just wants to know if their medication is real.

what this means for your conversations

If you're navigating this terrain (talking to clinicians about compounded medication, choosing between providers, deciding whether to trust a specific telehealth platform), a few practical points.

Ask which facility category the medication comes from. A legitimate telehealth platform should be able to tell you whether their compounded medications come from 503A or 503B facilities, name the actual pharmacy, and explain what their quality control looks like. Compounded by a US 503B pharmacy under FDA-registered conditions is a different answer than we get it from somewhere.

Verify the pharmacy. State board of pharmacy websites have public databases of licensed pharmacies. The FDA's 503B facility registry is public. You can verify that the facility your medication comes from is actually licensed and registered.

Distinguish prescription from non-prescription. Anything you receive in the mail from a compounding pharmacy should be tied to a specific prescription from a specific licensed prescriber. If you can buy peptides from a website without a prescription, that's not compounding. That's research chemicals or supplements.

Be patient with skeptical clinicians, but advocate. If your primary care doctor lumps compounded HRT or peptide therapy with research chemicals, the conversation can be productive if you bring specifics: This medication comes from a 503B outsourcing facility registered with FDA. It's prescribed by a licensed physician. The active ingredient has been used clinically for decades. That framing gives the clinician material to engage with rather than a position to argue against.

Know when to switch providers. Some clinicians are genuinely engaged with the compounded medication space and provide care thoughtfully. Some refuse to engage with anything outside the FDA-approved-commercial category. For specific medications (testosterone for women, peptides, bioidentical HRT in some formulations), the right provider often isn't a generalist. It's a clinician with specific compounding-aware practice. That's not bypassing the medical system; it's finding the right part of the medical system for the specific need.

where peptide therapy actually sits in this picture

For the specific case of peptide therapy at Pepvio and similar platforms, the picture is:

Sermorelin, PT-141, NAD+, oxytocin: these are compounded medications made by 503B outsourcing facilities, prescribed by licensed physicians via telehealth, regulated under standard compounding pharmacy frameworks. This is legitimate compounding-pharmacy medication, not gray market.

BPC-157, TB-500, Selank, Thymosin Alpha-1, CJC-1295, Ipamorelin, GHK-Cu: these are currently on the FDA's Category 2 bulk drug substances list, which specifically blocks 503A and 503B facilities from compounding them. As of mid-2026, the legitimate compounded supply for these specific peptides doesn't exist in the US. The reclassification announcement could change this. Until it does, anyone selling these peptides in the US is operating outside the legitimate compounded medicine framework: research chemicals, gray market, or international sources.

Cosmetic peptides (GHK-Cu in non-prescription skincare, some over-the-counter peptide products): these are regulated under cosmetic rules rather than drug rules, which is a separate regulatory category with different (lower) requirements.

The practical implication: when Sermorelin or PT-141 is prescribed through Pepvio, the medication you receive comes from a licensed 503B facility, is made under FDA-registered conditions, is dispensed against a specific prescription, and is part of the legitimate compounded medicine supply chain. Not gray market, not research chemical, not unregulated. The same product framework that makes custom-dosed thyroid medication or bioidentical estradiol cream available is what makes prescribed peptide therapy available.

When people imply that compounded peptide therapy is gray market, they're either confused about the regulatory categories or conflating legitimate compounded medication with the gray market that does exist for the Category-2 peptides. Both possibilities are worth gently correcting in conversation.

the honest summary

There are real differences between FDA-approved drugs, legitimate compounded medications, and gray-market research chemicals. The differences matter for safety, for quality, and for what the clinical conversation should actually look like.

If your primary care doctor uses not FDA-approved and unregulated gray market as if they're the same thing, that's a real misunderstanding worth gently pushing back on. Legitimate compounded medications come from licensed pharmacies under specific regulatory frameworks. They're prescribed by licensed physicians. They go through quality testing for potency, sterility, and stability. They're tracked, documented, and dispensed against specific prescriptions. None of this is the same as ordering BPC-157 from a research-chemical website.

The distinction also matters for your own decisions. If you're considering peptide therapy and you're talking to providers, the questions worth asking are about specific facilities, specific regulatory categories, and specific quality controls. Where does this medication come from? is a productive question. Is this FDA-approved? is a question that misses what's actually relevant for compounded medications.

For more on the specific regulatory framework around peptides, see the current state of peptide legality. For the specific gray-market vs legitimate-supply distinction around currently-Category-2 peptides, see BPC-157 and golfer's elbow and the various peptide-specific articles on this site that explicitly note the difference.

The broader point is that the US pharmaceutical system has more shapes than FDA-approved and not FDA-approved. The compounding category is its own thing, and it's the operational reality of a lot of legitimate medical practice. Knowing this is part of being a literate consumer of healthcare in 2026.